These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 20682020

  • 21. Effect of immunosuppressive regimen on acute rejection and liver graft function.
    Ziolkowski J, Paczek L, Niewczas M, Senatorski G, Oldakowska-Jedynak U, Wyzgal J, Foroncewicz B, Mucha K, Zegarska J, Nyckowski P, Zieniewicz K, Patkowski W, Krawczyk M, Ziarkiewicz-Wroblewska B, Gornicka B.
    Transplant Proc; 2003 Sep; 35(6):2281-3. PubMed ID: 14529915
    [Abstract] [Full Text] [Related]

  • 22. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial.
    Zuckermann A, Reichenspurner H, Birsan T, Treede H, Deviatko E, Reichart B, Klepetko W.
    J Thorac Cardiovasc Surg; 2003 Apr; 125(4):891-900. PubMed ID: 12698153
    [Abstract] [Full Text] [Related]

  • 23. Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study.
    Neu AM, Ho PL, Fine RN, Furth SL, Fivush BA.
    Pediatr Transplant; 2003 Jun; 7(3):217-22. PubMed ID: 12756047
    [Abstract] [Full Text] [Related]

  • 24. Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids.
    Tran HTB, Acharya MK, McKay DB, Sayegh MH, Carpenter CB, Auchincloss H, Kirkman RL, Milford EL.
    J Am Soc Nephrol; 2000 Oct; 11(10):1903-1909. PubMed ID: 11004222
    [Abstract] [Full Text] [Related]

  • 25. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation.
    Fisher RA, Stone JJ, Wolfe LG, Rodgers CM, Anderson ML, Sterling RK, Shiffman ML, Luketic VA, Contos MJ, Mills AS, Ferreira-Gonzalez A, Posner MP.
    Clin Transplant; 2004 Aug; 18(4):463-72. PubMed ID: 15233827
    [Abstract] [Full Text] [Related]

  • 26. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV.
    Transplantation; 2012 Jan 15; 93(1):73-81. PubMed ID: 22129761
    [Abstract] [Full Text] [Related]

  • 27. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation.
    Ekberg H, Bernasconi C, Tedesco-Silva H, Vítko S, Hugo C, Demirbas A, Acevedo RR, Grinyó J, Frei U, Vanrenterghem Y, Daloze P, Halloran P.
    Am J Transplant; 2009 Aug 15; 9(8):1876-85. PubMed ID: 19563339
    [Abstract] [Full Text] [Related]

  • 28. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.
    Ekberg H, Grinyó J, Nashan B, Vanrenterghem Y, Vincenti F, Voulgari A, Truman M, Nasmyth-Miller C, Rashford M.
    Am J Transplant; 2007 Mar 15; 7(3):560-70. PubMed ID: 17229079
    [Abstract] [Full Text] [Related]

  • 29. Optimization of the immunosuppressive protocol after lung transplantation.
    Reichenspurner H, Kur F, Treede H, Meiser BM, Deutsch O, Welz A, Vogelmeier C, Schwaiblmair M, Müller C, Fürst H, Briegel J, Reichart B.
    Transplantation; 1999 Jul 15; 68(1):67-71. PubMed ID: 10428269
    [Abstract] [Full Text] [Related]

  • 30. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
    Spagnoletti G, Citterio F, Favi E, Rossi E, Delreno F, De Santis I, Salerno MP, Gargiulo A, Castagneto M.
    Transplant Proc; 2009 May 15; 41(4):1175-7. PubMed ID: 19460509
    [Abstract] [Full Text] [Related]

  • 31. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation.
    Sarwal MM, Vidhun JR, Alexander SR, Satterwhite T, Millan M, Salvatierra O.
    Transplantation; 2003 Nov 15; 76(9):1331-9. PubMed ID: 14627912
    [Abstract] [Full Text] [Related]

  • 32. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation.
    Rostaing L, Cantarovich D, Mourad G, Budde K, Rigotti P, Mariat C, Margreiter R, Capdevilla L, Lang P, Vialtel P, Ortuño-Mirete J, Charpentier B, Legendre C, Sanchez-Plumed J, Oppenheimer F, Kessler M, CARMEN Study Group.
    Transplantation; 2005 Apr 15; 79(7):807-14. PubMed ID: 15818323
    [Abstract] [Full Text] [Related]

  • 33. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report.
    Jain A, Kashyap R, Dodson F, Kramer D, Hamad I, Khan A, Eghestad B, Starzl TE, Fung JJ.
    Transplantation; 2001 Sep 27; 72(6):1091-7. PubMed ID: 11579306
    [Abstract] [Full Text] [Related]

  • 34. Primary immunosuppression and outcome differences after heart transplantation: tacrolimus versus cyclosporine.
    Castel MA, Farrero M, Vallejos I, Cardona M, Regueiro A, Pérez-Villa F.
    Transplant Proc; 2011 Sep 27; 43(6):2244-6. PubMed ID: 21839245
    [Abstract] [Full Text] [Related]

  • 35. Humoral immunity after kidney transplantation: impact of two randomized immunosuppressive protocols.
    Legris T, Picard C, Moal V, Burtey S, Loundou A, Purgus R, Dussol B, Berland Y, Vacher-Coponat H.
    Ann Transplant; 2013 Nov 15; 18():622-34. PubMed ID: 24231646
    [Abstract] [Full Text] [Related]

  • 36. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
    Asberg A, Midtvedt K, Line PD, Narverud J, Holdaas H, Jenssen T, Reisaeter AV, Johnsen LF, Fauchald P, Hartmann A.
    Transplantation; 2006 Jul 15; 82(1):62-8. PubMed ID: 16861943
    [Abstract] [Full Text] [Related]

  • 37. Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus.
    Fuchs U, Zittermann A, Ensminger SM, Schulz U, Gummert JF.
    Transpl Immunol; 2014 Aug 15; 31(2):87-91. PubMed ID: 24932812
    [Abstract] [Full Text] [Related]

  • 38. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG, Winoto J, Chhabra D, Parker MA, Leventhal JR, Kaufman DB.
    Transplantation; 2007 May 27; 83(10):1324-9. PubMed ID: 17519781
    [Abstract] [Full Text] [Related]

  • 39. Ten-year observational follow-up of a randomized trial comparing cyclosporine and tacrolimus therapy combined with steroid withdrawal in living-donor renal transplantation.
    Kim J, Park J, Hwang S, Yoo H, Kim K, Park JB, Jang HR, Lee JE, Kim SJ, Kim YG, Kim DJ, Oh HY, Huh W.
    Clin Transplant; 2018 Sep 27; 32(9):e13372. PubMed ID: 30080284
    [Abstract] [Full Text] [Related]

  • 40. Tacrolimus and azathioprine versus cyclosporine and mycophenolate mofetil after lung transplantation: a retrospective cohort study.
    Celik MR, Lederer DJ, Wilt J, Eser D, Bacchetta M, D'Ovidio F, Sonett JR, Arcasoy SM.
    J Heart Lung Transplant; 2009 Jul 27; 28(7):697-703. PubMed ID: 19560698
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.